First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1
Open Access
- 14 November 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11), e0205139
- https://doi.org/10.1371/journal.pone.0205139
Abstract
Background Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-Env, "rcAd26"). Here we present the results of a first-in-human, placebo-controlled clinical trial to test the safety, immunogenicity and mucosal shedding of rcAd26 given orally. Methods Healthy adults were randomly assigned to receive a single oral dose of vaccine or placebo at 5:1 ratio in a dosage escalation of 10 boolean AND 8 to 10 boolean AND 11 rcAd26 VP (nominal doses) at University of Rochester Medical Center, Rochester, NY, USA. Participants were isolated and monitored for reactogenicity for 10 days post-vaccination, and adverse events were recorded up to day 112. Rectal and oropharyngeal secretions were evaluated for shedding of the vaccine. Humoral and cellular immune responses were measured. Household contacts were monitored for secondary vaccine transmission. Results We enrolled 22 participants and 11 household contacts between February 7 and June 24, 2015. 18 participants received one dose of HIV-1 vaccine and 4 participants received placebo. The vaccine caused only mild to moderate adverse events. No vaccine-related SAEs were observed. No infectious rcAd26 viral particles were detected in rectal or oropharyngeal secretions from any participant. Env-specific ELISA and ELISPOT responses were undetectable. No household contacts developed vaccine-induced HIV-1 seropositivity or vaccine-associated illness. Conclusions The highly attenuated rcAd26.MOS1.HIV-Env vaccine was well tolerated up to 10 boolean AND 11 VP in healthy, HIV-1-uninfected adults, though the single dose was poorly immunogenic suggesting the replicative capacity of the vector was too attenuated. There was no evidence of shedding of infectious virus or secondary vaccine transmission following the isolation period. These data suggest the use of less attenuated viral vectors in future studies of live, oral HIV-1 vaccines.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1033091)
- National Institute of Allergy and Infectious Diseases (AI060354)
- National Institute of Allergy and Infectious Diseases (AI096040)
- National Institute of Allergy and Infectious Diseases (AI124377)
- National Institute of Allergy and Infectious Diseases (AI126603)
- National Institute of Allergy and Infectious Diseases (AI128751)
- National Institute of Allergy and Infectious Diseases (OD024917)
This publication has 15 references indexed in Scilit:
- Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruitsVaccine, 2016
- Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionAnnals of Internal Medicine, 2016
- Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by VectorizationClinical and Vaccine Immunology, 2015
- Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of HumansThe Journal of Infectious Diseases, 2014
- Development of replication-competent viral vectors for HIV vaccine deliveryCurrent Opinion in HIV and AIDS, 2013
- A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruitsVaccine, 2013
- Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus MonkeysJournal of Virology, 2012
- A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adultsVaccine, 2008
- Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell ResponsesThe Journal of Immunology, 2007
- Oral immunisation against typhoid fever in Indonesia with Ty21a vaccineThe Lancet, 1991